This article was originally published in The Gray Sheet
The Health Industry Manufacturers Association will submit written testimony at a June 11 House Government Reform and Oversight/Human Resources Subcommittee hearing on institutional review boards. The hearing is expected to focus on four draft studies by the HHS Inspector General based on a review of 75 major IRBs. Pharmaceutical Research and Manufacturers of America Senior VP-Scientific/Regulatory Affairs Bert Spilker is expected to testify...
You may also be interested in...
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.